本文選題：IL-8 + DEFB�。� 參考：《青島大學》2017年碩士論文

【摘要】：目的在蛋白水平研究白細胞介素-8(IL-8)、防御素β-118(DEFB118)在卵巢漿液性腫瘤(漿液性囊腺瘤、交界性漿液性囊腺瘤、漿液性囊腺癌)組織中的表達差異。分析IL-8和DEFB118在卵巢漿液性囊腺癌組織中的表達與其臨床病理特征(FIGO分期、組織學分級、有無淋巴結轉移及腹膜轉移)之間的關系,以及兩種蛋白在癌組織中表達的相關性,來研究IL-8、DEFB-118在卵巢漿液性惡性腫瘤的發(fā)生、發(fā)展及防御方面的作用,為卵巢惡性腫瘤的發(fā)病機制、臨床診斷、治療靶點等提供理論依據,同時為卵巢惡性腫瘤的早期發(fā)現、診斷和治療及進一步研究提供一個新的方向。方法本研究采用免疫組織化學法對IL-8、DEFB118分別在46例卵巢漿液性囊腺瘤、32例卵巢交界性漿液性囊腺瘤、60例卵巢漿液性囊腺癌組織中的表達情況進行檢測,探討IL-8和DEFB118的表達與卵巢漿液性囊腺癌組織中FIGO分期、組織學分級、有無淋巴結轉移及腹膜轉移之間的關系,同時分析IL-8與DEFB-118在卵巢漿液性囊腺癌中的表達相關性。結果1.IL-8在卵巢漿液性囊腺癌組中的陽性表達率為78.33%,在卵巢漿液性囊腺瘤組的陽性表達率為15.22%,在卵巢交界性漿液性囊腺瘤組的陽性表達率為46.88%,卵巢漿液性囊腺癌組的陽性表達率顯著高于后兩者,其結果具有統(tǒng)計學意義(P0.05),兩兩比較,結果具有統(tǒng)計學意義(P0.017)。在卵巢漿液性囊腺癌組中,DEFB118的陽性表達率為68.33%,在卵巢交界性漿液性囊腺瘤組為50.00%,均高于卵巢漿液性囊腺瘤組的21.74%,其結果也具有統(tǒng)計學意義(P0.05),但卵巢交界性漿液性囊腺瘤組和卵巢漿液性囊腺癌組的陽性表達率比較無統(tǒng)計學意義(P0.017)。2.在卵巢漿液性囊腺癌組中,IL-8在FIGO分期晚期(Ⅲ-Ⅳ期)、高級別癌、發(fā)生淋巴結轉移及腹膜轉移的腫瘤組織中高表達,而在FIGO分期早期(Ⅰ-Ⅱ期)、低級別癌、無淋巴結及腹膜轉移的腫瘤組織中呈現低表達。同樣,DEFB118在FIGO分期晚期(Ⅲ-Ⅳ期)、高級別癌、發(fā)生淋巴結轉移及腹膜轉移的腫瘤組織中的表達明顯高于其在FIGO分期早期(Ⅰ-Ⅱ期)、低級別癌、無淋巴結及腹膜轉移的卵巢漿液性囊腺癌組織中。3.Spearman相關分析顯示:IL-8與DEFB118兩者在卵巢漿液性囊腺癌組織中的表達呈正相關(r=0.338,P0.05)。結論在卵巢漿液性腫瘤組織中,IL-8以及DEFB118在卵巢漿液性囊腺癌和卵巢交界性漿液性囊腺瘤的表達均高于卵巢漿液性囊腺瘤,IL-8在卵巢漿液性囊腺癌中的表達也高于卵巢交界性漿液性囊腺瘤,且IL-8以及DEFB118與卵巢漿液性囊腺癌的臨床病理特征有關,兩者具有一定相關性。提示卵巢漿液性囊腺癌的發(fā)生、發(fā)展及侵襲轉移可能與之有關。
[Abstract]:Objective to study the expression of interleukin-8 (IL-8) and defensin 尾 -118 (DEFB118) in ovarian serous tumors (serous cystadenoma, borderline serous cystadenoma and serous cystadenocarcinoma). To analyze the relationship between the expression of IL-8 and DEFB118 in ovarian serous cystadenocarcinoma and their clinicopathological features (Figo stage, histological grade, lymph node metastasis and peritoneal metastasis), and the correlation between the expression of IL-8 and DEFB118 in cancer tissues. To study the role of IL-8 DEFB-118 in the occurrence, development and defense of ovarian serous malignant tumors, and to provide theoretical basis for the pathogenesis, clinical diagnosis and therapeutic targets of ovarian malignant tumors, as well as for the early detection of ovarian malignant tumors. Diagnosis and treatment and further research provide a new direction. Methods the expression of IL-8 DEFB118 in 46 cases of ovarian serous cystadenoma and 32 cases of ovarian borderline serous cystadenoma was detected by immunohistochemistry in 60 cases of ovarian serous cystadenocarcinoma. To investigate the relationship between the expression of IL-8 and DEFB118 and Figo stage, histological grade, lymph node metastasis and peritoneal metastasis in ovarian serous cystadenocarcinoma, and to analyze the correlation between IL-8 and DEFB-118 expression in ovarian serous cystadenocarcinoma. The positive expression rate of IL-8 was 78.33 in ovarian serous cystadenocarcinoma, 15.22 in ovarian serous cystadenoma, 46.88 in borderline ovarian cystadenoma and 46.88 in ovarian serous cystadenocarcinoma. The positive expression rate was significantly higher than that of the latter two. The results were statistically significant (P0.05), pairwise comparison, the results were statistically significant (P0.017). The positive rate of DEFB118 was 68.33 in ovarian serous cystadenocarcinoma group and 50.00th in borderline serous cystadenoma group, which was higher than 21.74 in ovarian serous cystadenoma group. The results were also statistically significant (P0.05), but the ovarian borderline serous cystadenoma was also characterized by ovarian borderline serous cystadenoma. The positive expression rates of cystadenoma and ovarian serous cystadenocarcinoma were not statistically significant (P0.017) .2. In ovarian serous cystadenocarcinoma group, IL-8 was highly expressed in advanced Figo stage (鈪，

本文編號：2094146